Dowpharma sells UK assets

Dowpharma has sold its small molecules facilities in Mirfield and Cambridge, both in the UK, to Dr Reddy's. Although the actual transaction cost was not revealed, G V Prasad, vice-chairman and ceo of Dr Reddy's, said the cost was slightly above the business's $25m revenue. The acquisition will include the relevant business, customer contracts, associated products, process technology, intellectual property, trademarks as well as the transfer of the facilities. Dr Reddy’s will also have a non-exclusive license to Dow’s Pfenex Expression Technology for biocatalysis development.
Bloomberg
Money Control